PP-095 Dynamics of serum HBV DNA levels and MELD scores in fatal acute-on-chronic hepatitis B liver failure  by Lai, J. et al.
S72 Abstracts, 5th DICID
Science and Technological Fund of Anhui Province for
Outstanding Youth (No.10040606Y14).
PP-095 Dynamics of serum HBV DNA levels and MELD
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Hospital, Sun Yat-Sen University, 2The People’s Hospital of
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Background and Aims: Until now, it is still not very clear
what impact the progression and result in fatal outcomes
of acute-on-chronic hepatitis B liver failure (HB-ACLF).
Model for end-stage liver disease (MELD) scores system is
an internationally recognized to predict the pathogenetic
condition of the end-stage liver disease. The study is to
investigate the dynamics and clinical signiﬁcances of serum
HBV DNA levels and MELD scores in the terminal phase of
HB-ACLF.
Methods: 106 fatal patients with HB-ACLF were enrolled,
who had never accepted antiviral therapy or liver
transplantation. At three phases of 29 90 d, 8 28 d and
1 7 d before death, they were detected serum HBV DNA
levels by Realtime-PCR in order meanwhile MELD scores
were calculated.
Results: In 35 patients with HBeAg positive, HBV DNA levels
were 6.16±1.59 log10, 5.63±1.52 log10 and 5.12±2.13
log10 copies/ml while MELD scores were 19.03±7.51,
24.79±6.40 and 33.06±7.64 respectively. In 71 patients with
anti-HBe positive, HBV DNA levels were 4.63±1.82 log10,
5.77±1.74 log10 and 4.69±1.68 log10 copies/ml while MELD
scores were 24.01±6.32, 28.34±7.77 and 33.25±10.13 in
sequence. HBV DNA levels of HBeAg positive group were
signiﬁcantly higher than that of anti-HBe positive group at
the phase of 29 90 d (P < 0.05). But in the same group,
HBV DNA levels were no signiﬁcant difference among
three phases, regardless of HBVe system status. With the
exacerbation of the ill, MELD scores increased steadily and
signiﬁcant difference was found in all patients (P < 0.05).
Conclusions: To initiate HB-ACLF occurrence, HBeAg
positive patients need higher serum HBV DNA levels than
that of anti-HBe positive ones. Regardless of HBVe system
status, sustained high HBV DNA levels may promote the
disease worsened and be fatal to patients.
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Background: To compare the clinical features of
spontaneous decrease of HBV DNA level between Hepatitis B
e antigen (HBeAg)-positive and HBeAg-negative chronic
hepatitis B patients (CHB).
Methods: Dynamic change of HBV DNA level was observed
for 12 weeks in 315 cases with admission HBV DNA level
above 10,000 copies/mL. All patients had never been
treated with antiviral or immunoregulatory drugs during
this period. In the ﬁrst observation week, HBV DNA, HBeAg,
ALT, AST, total bilirubin (TBIL), prothrombin time (PT)
were detected. HBV DNA was redetected at the end of
observation period. These cases were divided into subgroups
according to HBeAg and HBV DNA decrease (HBeAg-negative
group, HBeAg-positive group, and each was subgrouped into
decreased subgroup and non-decreased subgroup).
Results: Among the 315 CHB patients, 171 patients (54.3%)
underwent spontaneous decrease of HBV DNA level within
12 weeks. 83 (55.0%) of 151 HBeAg-positive patients
underwent spontaneous decrease of HBV DNA level, while
88 (53.7%) of 164 HBeAg-negative patients underwent that.
The difference between the above two groups was not
signiﬁcant (c2 = 0.054, P = 0.816). Among HBeAg-positive
patients, AST, TBIL, PT were higher in patients with
spontaneous decrease of HBV DNA level than in those
without (t = 3.485- 4.156, P = 0.000 0.001). Among HBeAg-
negative patients, HBV DNA, ALT, AST, TBIL, PT were higher
in patients with spontaneous decrease of HBV DNA level than
in those withoutv (t = 5.224 2.476, P = 0.000 0.014).
Conclusion: Half of the observed CHB patients underwent
spontaneous decrease of HBV DNA level, and the worse the
hepatic function was, the higher incidence of spontaneous
decrease of HBV DNA level would be whenever HBeAg were
positive or not.
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mathematical model with adefovir
Y.T. Wu1, Y.M. Su1 *, L.Q. Min1. 1Mathematics and Physics
School, University of Science and Technology Beijing,
Beijing, China
Background: The time delay mathematical models are
often used to describe the process of HBV infection
and treatment. Based on the basic virus infection model
introduced by Nowak et al. and Park Soo’s data of adefovir,
we set up a time delay model to simulate the dynamic
behavior of free viral, here the time delay stands for the
time between viral entry into a target cell and production
of new virus particles.
Methods: The model is described by three variables: x,
y, v represent the numbers of susceptible cells, infected
cells, and free virus. The model include 12 parameters:
l, d, c, h, b, a, n, k, u, xmax, t, e-mt, where c is the
maximum proliferation rate of target cells, xmax is the
x population density at which proliferation shuts off, h and n
represent the efﬁcacy of the therapy, e-mt accounts for
cells that are infected at time t but die before becoming
productively infected t time units later, the meanings of
l, d, b, a, k, u are the same as those given in Nowak’s
model. During treatment, we chose { l, d, c, h, b, a, n, k,
u, xmax, t, e-mt} = {2.525×102, 3.79e-004, 3×10 6, 0.5,
40, 1.644e-003, 0.9999, 0.0749, 0.1679, 6.6623e+005, 1.8,
e-0.00002×1.8}.
Results: The simulation data of the free viral in our model
is consistent with the clinical data perfectly.
Conclusion: The result shows that our time delay anti-
HBV model may be used as a reference for comparing
the efﬁciency of different drugs, and other HBV infection
models.
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Background: Asymptomatic CK elevations were observed in
patients who received the telbivudine treatment. This study
is to analyze the factors related to this phenomenon.
